目的 建立卡度尼利单抗药物利用评价（DUE）标准，并以加权逼近理想排序（TOPSIS）法对卡度尼利单抗用药的合理性进行评价。方法 以卡度尼利单抗说明书为基础，以相关指导原则和诊疗指南为评价依据建立卡度尼利单抗的DUE标准；采用熵权法（EWM）对DUE标准各指标进行赋权，并运用加权TOPSIS法对江苏大学附属宜兴医院2024年4月—2025年7月使用卡度尼利单抗的归档病历进行用药合理性评价。结果 所建的卡度尼利单抗DUE标准包括3个一级指标和11个二级指标，权重较高的二级指标为药物剂量疗程（43.352%）、说明书适应证（26.214%）和联合用药（7.642%）。在纳入的164例病历中相对接近程度（C_i）最高为0.978 8，最低为0.229 3,C_i<0.6的有148例（90.24%）,0.6≤C_i<0.8的有4例（2.44%）,C_i≥0.8的有12例（7.32%）；用药不合理主要集中在说明书适应证和药物剂量疗程。结论 以加权TOPSIS法对卡度尼利单抗用药合理性进行评价，评价结果能充分地反映其在临床应用中的合理性，更精准地指导临床用药。

Objective To establish the drug utilization evaluation（DUE） standard of cadonilimab, and to evaluate the rationality of cardunilimab by weighted technique for order preference by similarity to ideal solution（TOPSIS） method. Methods Based on the instructions of cardunilimab, the DUE standard of cardunilimab was established based on the relevant guidelines and diagnosis and treatment guidelines. The entropy weight method（EWM） was used to weight each index of the DUE standard, and the weighted TOPSIS method was used to evaluate the rationality of medication using cardonilimab in Yixing Hospital Affiliated to Jiangsu University from April 2024 to July 2025. Results The established DUE criteria for cardunilimab included 3 primary indicators and 11 secondary indicators. The secondary indicators with higher weights were dose course（43.352 %）, instruction indications（26.214%）, and combination therapy（7.642 %）. Among the 164 included medical records, the highest relative proximity（C_i） was 0.978 8, the lowest was 0.229 3, 148 cases（90.24 %） had C_i ＜ 0.6, four cases（2.44 %） had 0.6 ≤ C_i ＜ 0.8, and 12 cases（7.32 %） had C_i ≥ 0.8; Irrational medication mainly focuses on the instructions and indications, and dosage and course of treatment. Conclusion The weighted TOPSIS method is used to evaluate the rationality of cardonilimab medication. The evaluation results can fully reflect its rationality in clinical application and guide clinical medication more accurately.

R979.1